Names | |
---|---|
Preferred IUPAC name
2,3-di(decanoyloxy)propyl decanoate | |
Other names
Tridecanoin; Glyceryl tricaprate
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChemSpider | |
EC Number |
|
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C33H62O6 | |
Molar mass | 554.853 g·mol−1 |
Appearance | White (light yellow?) crystals[1] |
Melting point | 31 °C (88 °F; 304 K)[1] |
Thermochemistry | |
Heat capacity (C)
|
1109 J/mol·K[2] |
Std enthalpy of
formation (ΔfH⦵298) |
-1985.1 kJ/mol[2] |
Std enthalpy of
combustion (ΔcH⦵298) |
19861.4 ± 1.8 kJ/mol[2] |
Hazards | |
Occupational safety and health (OHS/OSH): | |
Main hazards
|
Not classified as a hazardous substance |
Lethal dose or concentration (LD, LC): | |
LD50 (median dose)
|
>10 g/kg (mouse, intravenous)[3] |
Safety data sheet (SDS) | External MSDS |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Tracking categories (test):
Tricaprin or tridecanoin is a triglyceride of capric acid.[4] Its formula is C33H62O6.
Occurrence edit
Tricaprin occurs naturally in the seeds of Umbellularia californica, a hardwood tree native to North America.[5]
Production edit
Uses edit
Tricaprin is used as an additive to diesel fuel[6] and as part of current and speculative biodiesels.[7][8]
Pharmacological edit
Tricaprin has been indicated as a possible drug to increase the production of insulin and decrease the production of androgen in the body when taken orally.[9] It, along with other medium-chain triglycerides, has been studied as a treatment option to prevent ruptures of abdominal aortic aneurysm,[10] and has been specifically studied as a regulator of membrane functions[11] and in the heart to facilitate lipolysis.[12]
See also edit
References edit
- ^ a b "Tricaprin". Sigma-Aldrich. June 18, 2023.
- ^ a b c Decanoic acid, 1,2,3-propanetriyl ester in Linstrom, Peter J.; Mallard, William G. (eds.); NIST Chemistry WebBook, NIST Standard Reference Database Number 69, National Institute of Standards and Technology, Gaithersburg (MD)
- ^ Wretlind A (October 1957). "The toxicity of low-molecular triglycerides". Acta Physiologica Scandinavica. 40 (4): 338–343. doi:10.1111/j.1748-1716.1957.tb01502.x. PMID 13478501.
- ^ Aimo L. "tricaprin (CHEBI:77388)". ChEBI. Retrieved April 12, 2024.
- ^ Reynolds T, Dring JV, Hughes C (December 1991). "Lauric acid-containing triglycerides in seeds of umbellularia californica nutt. (Lauraceae)". Journal of the American Oil Chemists' Society. 68 (12): 976–977. doi:10.1007/BF02657546. ISSN 0003-021X.
- ^ Eiteman MA, Goodrum JW (1993). "Rheology of the Triglycerides Tricaproin, Tricaprylin, and Tricaprin and of Diesel Fuel". Transactions of the ASAE. 36 (2): 503–507. doi:10.13031/2013.28366. ISSN 2151-0059.
- ^ Goodrum JW, Eiteman MA (April 1996). "Physical properties of low molecular weight triglycerides for the development of bio-diesel fuel models". Bioresource Technology. 56 (1): 55–60. doi:10.1016/0960-8524(95)00167-0.
- ^ Ferreira IM, de Ganzeli L, Rosset IG, Yoshioka SA, Porto AL (January 2017). "Ethylic Biodiesel Production Using Lipase Immobilized in Silk Fibroin-Alginate Spheres by Encapsulation". Catalysis Letters. 147 (1): 269–280. doi:10.1007/s10562-016-1917-0. ISSN 1011-372X.
- ^ "Tricaprin (Code C153424)". NCI Thesaurus. Retrieved April 12, 2024.
- ^ Kugo H, Sugiura Y, Fujishima R, Jo S, Mishima H, Sugamoto E, et al. (April 2023). "Tricaprin can prevent the development of AAA by attenuating aortic degeneration". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 160: 114299. doi:10.1016/j.biopha.2023.114299. PMID 36724640.
- ^ Ro SY, Choi HM, Choi SH, Lee SW, Lim SJ (July 2023). "Tricaprin as a membrane permeability regulator: sustained small hydrophilic substance release from liposomes". Journal of Pharmaceutical Investigation. 53 (4): 539–548. doi:10.1007/s40005-023-00621-2. ISSN 2093-5552.
- ^ Miyauchi H, Hirano KI, Nakano Y, Shimada K, Nishikawa M, Yamamoto H, et al. (2022). "123I-BMIPP Scintigraphy Shows That CNT-01 (Tricaprin) Improves Myocardial Lipolysis in Patients with Idiopathic Triglyceride Deposit Cardiomyovasculopathy: First Randomized Controlled, Exploratory Trial for TGCV". Annals of Nuclear Cardiology. 8 (1): 67–75. doi:10.17996/anc.22-00167. PMC 9749752. PMID 36540180.
This page will be placed in the following categories if it is moved to the article namespace.
Categories: